MedTrace Logo

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

NCT04672512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2022-02-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125329 after single and multiple ascending oral doses of CORT125329 lipid capsule formulations in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

CORT125329 lipid capsule formulation

CORT125329 lipid capsule formulation 1 or 2 for oral administration

DRUG

Placebo

Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration

DRUG

Prednisone

Prednisone tablet for oral administration

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sharan Sidhu, MBChB, BAO, MRCS, MFPM · Quotient Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2022-01-17
Completion
2022-01-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04672512 on ClinicalTrials.gov